HELSINKI, Aug. 15,
2024 /PRNewswire/ -- Nanoform Finland Plc
("Nanoform"), the medicine performance-enhancing company, today
announced that it is to enter into a pre-clinical development
agreement with the Plasma-derived Therapies Business Unit of Takeda
Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company
headquartered in Japan, to develop
innovative plasma-derived therapy formulations for the treatment of
rare conditions.
Following the completion of in vitro proof of concept studies of
a novel plasma-derived therapy formulation, Nanoform will provide
non-GMP nanomaterial to Takeda for in vivo studies. The
first results of these studies are expected by early 2025.
"Direct nanoforming of biologics is a promising new approach to
allow more life-changing large-molecule medicines to reach the
market," commented Dr. Edward Haeggström, CEO of
Nanoform. "We look forward to entering in vivo studies
together with Takeda and expanding our already very positive
relationship."
The value of this pre-clinical (non-GMP) project is in line with
Nanoform's guided business model of €0.05m to €0.5m per non-GMP
project. It is the intention of both Nanoform and Takeda to develop
medicine candidates to clinic and then take them as products to the
market.
Nanoform Biologics' nanoforming technology can deliver
large-molecule drug particles of tuneable size and morphology,
while retaining biological activity. The technology can be applied
across the biologics field, from 1 to 150KDa, to enable novel
routes of delivery, enhance drug loading, tailor release profiles
and engineer new drug combinations.
For further inquiries, please contact:
Nanoform
Christian Jones
Chief Commercial Officer
christian.jones@nanoform.com
+44 (0)7804 474771
For investor relations and financial media queries, please
contact:
Nanoform
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 (0)7686 650 11
For media inquiries please contact:
Chris Halling, Orientation Marketing
chris.halling@orientation.agency
+44 (0)7580 041073
About plasma-derived therapies (PDTs)
Used therapeutically for more than 100 years, plasma can be
transformed into lifesaving and life-sustaining therapies for
people with rare and complex chronic diseases - often patients with
a lifelong condition and no other alternative treatment options.
Global demand for plasma-derived therapies has greatly increased
over the past 20 years and is continuing to grow due to more rare
diseases being diagnosed, more patients being identified, higher
standards of care and broader access to treatment.
About Nanoform
Nanoform is the medicine performance-enhancing company that
leverages best-in-class innovative nanoparticle engineering
technologies, expert formulation, and scalable GMP API
manufacturing to enable superior medicines for patients. The
company focuses on reducing clinical attrition and on enhancing
drug molecules' performance through its nanoforming technologies
and formulation services, from pre-formulation to commercial scale.
Nanoform will help improve bioavailability and drug delivery
profiles, drive differentiation, patient adherence and extend the
lifecycle potential of products. Nanoform's shares are listed on
the Premier-segment of Nasdaq First North Growth Market in
Helsinki (ticker: NANOFH) and
Stockholm (ticker: NANOFS).
Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588
68 570. For more information, please visit
www.nanoform.com.
Nanoform Forward-Looking Statements
This press release contains forward-looking statements,
including, without limitation, statements regarding Nanoform's
strategy, business plans and focus. The words "may", "will",
"could", "would", "should", "expect", "plan", "anticipate",
"intend", believe", "estimate", "predict", "project", "potential",
"continue", "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, any related to
Nanoform's business, operations, clinical trials, supply chain,
strategy, goals and anticipated timelines, competition from other
companies, and other risks described in the Report of the Board of
Directors and Financial Statements for the year ended December 31, 2023 as well as our other past
disclosures. Nanoform cautions you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. Nanoform disclaims any obligation to publicly update
or revise any such statements to reflect any change in expectations
or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent Nanoform's views only as
of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nanoform/r/nanoform-collaborates-with-takeda-on-their-plasma-derived-therapy-development,c4024560
The following files are available for download:
https://mb.cision.com/Main/18905/4024560/2945650.pdf
|
Release
|
View original
content:https://www.prnewswire.com/news-releases/nanoform-collaborates-with-takeda-on-their-plasma-derived-therapy-development-302223222.html
SOURCE Nanoform